Arcellx Doses First Patient in Phase 1 Study of ACLX-001 in Relapsed or Refractory Multiple Myeloma

Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).

The Phase 1 clinical trial is currently evaluating the novel ARC-SparX …

Full story available on Benzinga.com